Skip to main content
An official website of the United States government
Julia Gage headshot

Julia Gage, Ph.D., M.P.H.

Program Director
240-604-1554
|

Julia Gage, Ph.D., M.P.H., joined the Center for Global Health (CGH) in 2023, as a Program Officer, to support the CGH efforts to develop embedded implementation research that facilitates the introduction of human papillomavirus (HPV)-based cervical cancer screening and treatment within public health systems in low-resource health systems while rapidly disseminating best practices. Prior to joining CGH, Dr. Gage served in NCI's Division of Cancer Epidemiology and Genetics (DCEG), where her research focused on translating novel HPV natural history discoveries into improved screening and diagnosis for cervical precancer. In particular, Julia has pursued scientific investigations to identify and bring forth new technologies for cervical cancer prevention to low medical resource settings, resulting in over 130 publications.

Dr. Gage served as NCI-lead for multiple studies during her time in DCEG, including: the NCI/Brazilian Management of Risk of Cervical Cancer (MARCO) study to evaluate the effectiveness and cost-effectiveness of novel cervical screening and triage strategies, a Rwandan study of the impact of prophylactic HPV vaccination on HPV immunity and HPV infection in women living with HIV, and Project Itoju (Care) – Epidemiologic and molecular features of cervical cancer in Nigeria. While at NCI, Julia has enjoyed working with governmental partners on national screening programs in El Salvador and Peru. She also has served on numerous World Health Organization Screening and Management Guidelines committees.

Key Publications

Mix J, Saraiya M, Hallowell BD, et al. Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and ManagementJ Natl Cancer Inst. 2022;114(6):845-853. doi:10.1093/jnci/djac034

Bigner DD, Brown M, Coleman RE, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary reportJ Neurooncol. 1995;24(1):109-122. doi:10.1007/BF01052668

Ribeiro A, Corrêa F, Migowski A, et al. Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact StrategiesCancer Prev Res (Phila). 2021;14(10):919-926. doi:10.1158/1940-6207.CAPR-21-0110

  • Posted:
Email